Clinical trial
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
NCT02906163 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
- Lead sponsor
- SciClone Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- October 31, 2016
- Completion date
- January 31, 2020
- Enrollment
- 188 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
egfr mutation positive non small cell lung cancer